| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3744 | Nsc13987 | Novel inhibitor of Nef-calnexin interaction |
|
| DCC3745 | Nsc-140873 | Inhibitor of the RUNX1-CBFβ interaction |
|
| DCC3746 | Nsc16168 | Specific inhibitor of ERCC1-XPF with no effect on both HhaI and XPG |
|
| DCC3747 | Nsc175176 | Novel potent and selective serotonin reuptake inhibitor (SSRI) |
|
| DCC3748 | nsc-176327 | Selective G-quadruplex inducer of the human telomeric sequence; Stabilizer of the G-quadruplex formed by the MYC promoter sequence; Anti-neoplastic effects in wild-type p53, p53-mutant or p53-deficient human colon cancer cells. |
|
| DCC3749 | Nsc-176377 | Non-nucleoside reverse transcriptase inhibitor |
|
| DCC3750 | Nsc-18725 | Novel inhibitor of growth of intracellular Mycobacterium tuberculosis, inducing autophagy in differentiated THP-1 macrophages |
|
| DCC3751 | nsc-20596 | Capturer of kinase-insertion domain receptor (KDR) from a solution, while allowing the captured KDR to bind with the solution-phase vascular endothelial growth factor (VEGF) |
|
| DCC3752 | Nsc24048 | Novel inhibitor of ABCG2 transporter function |
|
| DCC3753 | Nsc-24198 | Novel potent SHP2 Inhibitor with Anti-Proliferative Activity in Breast Cancer Cell Lines |
|
| DCC3754 | Nsc24674 | Novel 3C-like protease inhibitor of SARS-CoV-2 |
|
| DCC3755 | Nsc-2488 [5459-61-0] | Novel Rho-Kinase-II Inhibitor with Vasodilatory Activity |
|
| DCC3756 | nsc-252359 | Specific Ligand for Stem Loop 3 Ribonucleic Acid of the Packaging Signal Ψ of Human Immunodeficiency Virus-1 |
|
| DCC3757 | Nsc265473 | Novel substrate of ABCG2 |
|
| DCC3758 | Nsc-279287 | Novel Inhibitor of the p53-mdm2 Interaction, Activating p53-Dependent Transcription in mdm2-Overexpressing Cells |
|
| DCC3759 | Nsc-2888 | Novel Rho-Kinase-II Inhibitor with Vasodilatory Activity |
|
| DCC3760 | Nsc-299202 | Novel potent gonist of Human G Protein-Coupled Receptor-35 (hGPR35) (EC50 8 nM) |
|
| DCC3761 | Nsc30049 | Novel inhibitor of Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations |
|
| DCC3762 | Nsc-311068 | Novel selective inhibitor of TET1 transcription and 5-hydroxymethylcytosine (5hmC) modification, effectively inhibiting cell viability in AML with high expression of TET1 |
|
| DCC3763 | Nsc-33353 | Potent inhibitor of the AcrAB-TolC efflux pump in Escherichia coli, potentiating the antibacterial activities of novobiocin and erythromycin upon binding to the membrane fusion protein AcrA |
|
| DCC3764 | Nsc-339579 | Novel potent Mycobacterium tuberculosis DHFR inhibitor |
|
| DCC3765 | Nsc339614 Potassium Salt | Selective potentiator at GluN1/GluN2C and GluN1/GluN2D receptors |
|
| DCC3766 | Nsc-347518 | DT-diaphorase inhibitor |
|
| DCC3767 | Nsc-4231 | Novel Rho-Kinase-II Inhibitor with Vasodilatory Activity |
|
| DCC3768 | nsc48693 Dihydrochloride | Potent apoptosis inducer in pancreatic cancer cells |
|
| DCC3769 | Nsc52101 | Novel potent inhibitor of Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein |
|
| DCC3770 | Nsc-55158 | Novel antagonist of the Grb7 SH2 domain; Antitumor Agent |
|
| DCC3771 | Nsc56452 | Novel specific inhibitor of EGF receptor autophosphorylation and cell proliferation in HeLa cells by disrupting allosteric activation of EGF-stimulated dimer |
|
| DCC3772 | Nsc-57148 | Novel antagonist of the Grb7 SH2 domain; Antitumor Agent |
|
| DCC3773 | Nsc-57774 | Novel potent SHP2 Inhibitor with Anti-Proliferative Activity in Breast Cancer Cell Lines |
|
